About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a company based in Edmonton (Canada) founded in 1993.. The company has 130 employees as of December 31, 2024. Aurinia Pharmaceuticals offers products and services including LUPKYNIS. Aurinia Pharmaceuticals operates in a competitive market with competitors including Moderna, Forge Biologics, Annexon, Ventyx Biosciences and Dren Bio, among others.
- Headquarter Edmonton, Canada
- Employees 130 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Aurinia Pharmaceuticals Inc
-
Annual Revenue
$235.13 M33.97as on Dec 31, 2024
-
Net Profit
$5.75 M107.37as on Dec 31, 2024
-
EBITDA
$33.52 M146.77as on Dec 31, 2024
-
Latest Funding Round
$28.75 M (USD), Post-IPO
Dec 28, 2016
-
Investors
Mogo
& 9 more
-
Employee Count
130
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol AUPH in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Aurinia Pharmaceuticals
Aurinia Pharmaceuticals offers a comprehensive portfolio of products and services, including LUPKYNIS. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for lupus nephritis to prevent kidney damage in patients.
Unlock access to complete
Unlock access to complete
Leadership Team
31 people
Software Development Team
10 people
Operations Team
8 people
Finance and Accounting
7 people
Sales and Marketing
6 people
Scientific Team
5 people
Field Team
4 people
Product Management Team
3 people
Unlock access to complete
Funding Insights of Aurinia Pharmaceuticals
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $28.8M
-
First Round
First Round
(07 Sep 2013)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2016 | Amount | Post-IPO - Aurinia Pharmaceuticals | Valuation |
investors |
|
| Aug, 2016 | Amount | Post-IPO - Aurinia Pharmaceuticals | Valuation |
investors |
|
| Jun, 2016 | Amount | Post-IPO - Aurinia Pharmaceuticals | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Aurinia Pharmaceuticals
Aurinia Pharmaceuticals has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Mogo, RA Capital and Abingworth. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early stage venture capital firm investing in US
|
Founded Year | Domain | Location | |
|
A life sciences investment firm focused on novel therapeutics is operated.
|
Founded Year | Domain | Location | |
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Aurinia Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Aurinia Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Aurinia Pharmaceuticals Comparisons
Competitors of Aurinia Pharmaceuticals
Aurinia Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Forge Biologics, Annexon, Ventyx Biosciences and Dren Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
Therapeutics for autoimmune diseases are developed by the company.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies are developed for cancer, autoimmune, and serious diseases.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Aurinia Pharmaceuticals
Frequently Asked Questions about Aurinia Pharmaceuticals
When was Aurinia Pharmaceuticals founded?
Aurinia Pharmaceuticals was founded in 1993 and raised its 1st funding round 20 years after it was founded.
Where is Aurinia Pharmaceuticals located?
Aurinia Pharmaceuticals is headquartered in Edmonton, Canada. It is registered at Edmonton, Alberta, Canada.
How many employees does Aurinia Pharmaceuticals have?
As of Dec 31, 2024, the latest employee count at Aurinia Pharmaceuticals is 130.
What is the annual revenue of Aurinia Pharmaceuticals?
Annual revenue of Aurinia Pharmaceuticals is $235.13M as on Dec 31, 2024.
What does Aurinia Pharmaceuticals do?
Aurinia Pharmaceuticals was founded in 1993 in Edmonton, Canada, and operates in the pharmaceutical sector focused on autoimmune conditions. Therapeutics are developed, including the lead candidate voclosporin for lupus nephritis treatment. Additional pipeline assets encompass AUR200, an immune modulator targeting BAFF and APRIL activity, and AUR300, a peptide designed for autoimmune and fibrotic diseases. Operations center on advancing these candidates through clinical development.
Who are the top competitors of Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals's top competitors include Moderna, Forge Biologics and Annexon.
What products or services does Aurinia Pharmaceuticals offer?
Aurinia Pharmaceuticals offers LUPKYNIS.
Is Aurinia Pharmaceuticals publicly traded?
Yes, Aurinia Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol AUPH.
Who are Aurinia Pharmaceuticals's investors?
Aurinia Pharmaceuticals has 10 investors. Key investors include Mogo, RA Capital, Abingworth, ILJIN, and venBio.
What is Aurinia Pharmaceuticals's ticker symbol?
The ticker symbol of Aurinia Pharmaceuticals is AUPH on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.